ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Japanese Firms Link With U.S. Institutes

by Michael McCoy
April 13, 2015 | APPEARED IN VOLUME 93, ISSUE 15

Two Japanese drug companies have signed R&D pacts with U.S. research institutes. Astellas Pharma will work with the University of Texas MD Anderson Cancer Center on a new treatment for patients with acute myeloid leukemia. The pact, which includes a payment of up to $26 million by Astellas, will focus on h8F4, a humanized monoclonal antibody invented by MD Anderson professor Jeffrey J. Molldrem. Daiichi Sankyo, meanwhile, will work with California’s Sanford-Burnham Medical Research Institute to develop a small-molecule cardiovascular-metabolic disease treatment that arose from work by a Sanford-Burnham scientist.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment